ClinicalTrials.gg
Drug

Fidaxomicin clinical trials

Also written Dificid, OPT-80 and PAR-101.

studies test it
23
open now
2
in phase 3
6
first study started
2004

How each study uses Fidaxomicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Fidaxomicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
27 May 2011 · DIFICID · NDA 201699 (FDA, Drugs@FDA)
European Union
5 Dec 2011 · Dificlir · EMEA/H/C/002087 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Fidaxomicin
18
Dificlir
7
Fidaxomicin 200 mg
2

Brand

Dificid
11

Development codes

OPT-80
7
PAR-101
4
ASP2819
2

Studies by the year they started

23 studies that test it; most in 2012 (5)

Studies that test Fidaxomicin, by start year
YearStudies
20041
20062
20125
20132
20144
20153
20161
20171
20181
20191
20251
20261

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3
Phase 3
6
Phase 4
11
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 12 · Other 11

Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (5) · Astellas Pharma Europe Ltd. (3) · Astellas Pharma Europe B.V. (2) · Astellas Pharma Inc (1) · University of Michigan (1) · Duke University (1) · Hartford Hospital (1) · Astellas Pharma Global Development, Inc. (1)

Often tested with

Tested in the same studies.

Vancomycin (6) · Metronidazole (1) · Rosuvastatin (1) · Bean (1) · Fecal Microbiota Transplantation (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 1 phase 3 study under way

Fidaxomicin is the comparator. A study of two new drugs counts under both.

  • 1Vancomycin · McGill University Health Centre/Research Institute of the McGill University Health Centre · next primary completion Jul 2031
Reaching primary completion within a year · 1

Studies that test Fidaxomicin.

Studies

Open first, then newest update. How each study uses Fidaxomicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 23

See all 23 studies that test Fidaxomicin →

As the comparator · 4 — what is tested is compared with Fidaxomicin

Codes

What other systems call Fidaxomicin · ClinicalTrials.gg INT006797

  • MeSH (NLM) D000077732FidaxomicinConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) Z5N076G8YQFIDAXOMICINConfirmed FDA, NLM, Wikidata
  • RxNorm 1111103One source FDA
  • Wikidata Q111242331fidaxomicinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C66979FidaxomicinOne source FDA
  • DrugBank DB08874One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.